Photo by nci from unsplash
3509Background: Triple chemotherapy with an anti-EGFR reported promising activity with some safety concerns in single arm phase II trials. This trial evaluated activity and safety of mFOLFOXIRI + p... Click to show full abstract
3509Background: Triple chemotherapy with an anti-EGFR reported promising activity with some safety concerns in single arm phase II trials. This trial evaluated activity and safety of mFOLFOXIRI + p...
Keywords:
phase;
trial;
versus folfoxiri;
mfolfoxiri panitumumab;
panitumumab versus;
aio
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!